Clinical Research Directory
Browse clinical research sites, groups, and studies.
Travoprost Intraocular Implant in Conjunction With Cataract Surgery
Sponsor: Glaukos Corporation
Summary
Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular hypertension will undergo screening and washout from IOP-lowering medication, if applicable. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria and who undergo successful cataract extraction with implantation of a posterior chamber intraocular lens (PC-IOL) will receive a travoprost intraocular implant and followed up for 12 months.
Official title: Multicenter, Open-label, Single-arm Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With Cataract Surgery
Key Details
Gender
All
Age Range
45 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-09-11
Completion Date
2024-12-20
Last Updated
2024-06-03
Healthy Volunteers
No
Conditions
Interventions
iDose TR
anchored intracameral implant containing travoprost
Locations (1)
Glaukos Clinical Study Site
Yerevan, Armenia